Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.

Hamid O. et al, (2024), J Clin Oncol

Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.

Jakobsen NA. et al, (2024), Cell Stem Cell

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.

Gerds AT. et al, (2024), Blood Adv

Alternative platelet differentiation pathways initiated by nonhierarchically related hematopoietic stem cells.

Carrelha J. et al, (2024), Nat Immunol

Access divergence to new cancer medicines in the United Kingdom.

Lythgoe MP. et al, (2024), Eur J Cancer, 207

An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma.

Baxter MA. et al, (2024), ESMO Open, 9

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML

Risueño A. et al, (2024), Leukemia Research, 140

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.

Luke JJ. et al, (2024), J Immunother Cancer, 12

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.

Elez E. et al, (2024), BMC Cancer, 24

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).

Spiliopoulou P. et al, (2024), J Exp Clin Cancer Res, 43

Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination.

Watson RA. et al, (2024), Journal for immunotherapy of cancer, 12

New role of fat-free mass in cancer risk linked with genetic predisposition.

Harris BHL. et al, (2024), Sci Rep, 14

Generating human bone marrow organoids for disease modeling and drug discovery

Olijnik A-A. et al, (2024), Nature Protocols

Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.

Larkin J. et al, (2024), Cell Rep Med, 5

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors

Janku F. et al, (2024), Cancers, 16

Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.

Dixon-Zegeye M. et al, (2024), Trials, 25

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.

Oh ST. et al, (2024), EJHaem, 5, 105 - 116

Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML

Wang Z. et al, (2024), BLOOD, 144, 2749 - 2751

Implementing human bone marrow organoids to interrogate microenvironmental influences on the efficacy of blood cancer immunotherapies

Wong ZC. et al, (2024), CANCER RESEARCH, 84

Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

Mead AJ. et al, (2024), BLOOD, 144, 3186 - 3187